title: RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis.
abstract: Human renal cell carcinoma (HRCC) is characterized by a high level of resistance to all treatment modalities. Therefore, the investigation of global gene expression in HRCC might help understand its biologic behavior and develop treatment strategies. Using cDNA microarray analysis, we initially compared gene expression profiles between HRCCs and adjacent normal tissues, and found that 87 were up-regulated and 127 genes were down-regulated. Next, a subset of genes, twofold differentially expressed, were validated by Northern blotting. Unexpectedly, caveolin-1, a gene reported to be a tumor suppressor gene, was found to be up-regulated in HRCC tissues. Expression level of caveolin-1 in SN12CPM6 (high metastatic clone) was higher than in SN12C (low metastatic clone), and SN12CPM6 was more resistant to doxorubicin (DXR) than SN12C. Caveolin-1 gene was slightly induced in surviving SN12C cells after DXR treatment. Furthermore, SN12CPM6-siCav1 cells, which were transfected with siRNA of cavelon-1 gene, were more sensitive to DXR, compared to SN12CPM6, but reduction of caveolin-1 gene expression did not affect tumor formation in subcapsule of kidney and lung metastasis. On the other hand, induction of caveolin-1 gene affected the production of lung metastasis under anti-cancer drug treatment: the incidence of pulmonary metastasis was significantly lower in SCID mice injected with SN12CPM6-siCav1 cells, and the number of pulmonary nodules decreased significantly (p = 0.0004). The above results together suggest that caveolin-1 may confer a growth advantage to cancer cells during DXR chemotherapy and surviving HRCC cells eventually might develop lung metastasis.
authors.affiliation: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
authors.forename: Juwon
authors.initials: J
authors.lastname: Park
authors.forename: Eunkyung
authors.initials: E
authors.lastname: Bae
authors.forename: Chansu
authors.initials: C
authors.lastname: Lee
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Yoon
authors.forename: Yang Seok
authors.initials: YS
authors.lastname: Chae
authors.forename: Kwang-Sung
authors.initials: KS
authors.lastname: Ahn
authors.forename: Nam Hee
authors.initials: NH
authors.lastname: Won
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000473:pathology*; D051242:Caveolin 1 / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D015536:Down-Regulation / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology*; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D009362:Neoplasm Metastasis / Q000517:prevention & control; D034622:RNA Interference / Q000502:physiology*; D034741:RNA, Small Interfering / Q000235:genetics; D014162:Transfection; D014183:Transplantation, Heterologous; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000903:Antibiotics, Antineoplastic; D051242:Caveolin 1; D034741:RNA, Small Interfering; D004317:Doxorubicin
references.citation: Cancer Res. 1997 Nov 15;57(22):5189-95
references.pmid: 9371523
references.citation: Surg Today. 2003;33(7):486-90
references.pmid: 14506991
references.citation: J Biol Chem. 1998 Dec 4;273(49):32380-3
references.pmid: 9829965
references.citation: J Urol. 2006 Jun;175(6):2302-6
references.pmid: 16697863
references.citation: Urol Res. 2000 Apr;28(2):86-92
references.pmid: 10850629
references.citation: APMIS. 2009 Jul;117(7):477-87
references.pmid: 19594487
references.citation: J Urol. 1990 Sep;144(3):755-9
references.pmid: 1974934
references.citation: Cancer Biol Ther. 2004 Oct;3(10):931-41
references.pmid: 15539932
references.citation: J Biol Chem. 2004 Oct 1;279(40):42270-8
references.pmid: 15263006
references.citation: J Bone Miner Res. 2007 Jan;22(1):37-44
references.pmid: 17032147
references.citation: Anticancer Drugs. 2003 Apr;14(4):281-7
references.pmid: 12679732
references.citation: Br J Cancer. 2004 Aug 31;91(5):959-65
references.pmid: 15305200
references.citation: Clin Cancer Res. 1998 Aug;4(8):1873-80
references.pmid: 9717814
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6315S-21S
references.pmid: 15448024
references.citation: Cancer Res. 2001 Jun 1;61(11):4386-92
references.pmid: 11389065
references.citation: Oncogene. 1997 Nov 27;15(22):2727-33
references.pmid: 9400999
references.citation: J Nephrol. 2009 Nov-Dec;22(6):708-15
references.pmid: 19967649
references.citation: Br J Cancer. 2003 Nov 17;89(10):1909-13
references.pmid: 14612902
references.citation: BJU Int. 2004 Feb;93(3):291-6
references.pmid: 14764125
references.citation: Curr Opin Cell Biol. 1996 Aug;8(4):542-8
references.pmid: 8791446
references.citation: Lung Cancer. 2008 Jan;59(1):105-10
references.pmid: 17850918
references.citation: Cancer Biol Ther. 2004 Oct;3(10):954-9
references.pmid: 15326378
references.citation: Oncogene. 1998 Mar;16(11):1391-7
references.pmid: 9525738
references.citation: World J Urol. 1994;12(4):214-23
references.pmid: 7820144
references.citation: Am J Pathol. 2002 Nov;161(5):1647-56
references.pmid: 12414512
references.citation: J Biol Chem. 2000 Jul 7;275(27):20847-52
references.pmid: 10781609
references.citation: J Biol Chem. 2005 Jul 1;280(26):25134-45
references.pmid: 15802273
references.citation: Mol Immunol. 2010 Feb;47(5):1047-57
references.pmid: 20004976